Author

Lenka Munoz

The University of SydneyORCID 0000-0002-7625-5646Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Emma G. KempeiD· 2 shared Yuchen Feng· 2 shared Andrew P. MontgomeryiD· 1 shared Anthony Simon DoniD· 1 shared Ariadna RecasensiD· 1 shared Aude Touffu· 1 shared Brett William StringeriD· 1 shared Brianna Chen· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Emma G. KempeORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma

George L. Joun, Emma G. Kempe, Brianna Chen, Jayden Sterling, Ramzi H. Abbassi, Dana Friess, Matthew Singleton, Chandra Choudhury, Oana C. Marian, Willem Daniel du Preez, Ariadna Recasens, Teleri Clark, Tian Y. Du, Jason K. K. Low, Hani Kim, , Lenka Munoz

This study identifies PRDM9 as a factor promoting survival of drug-tolerant persister cells in glioblastoma through metabolic rewiring and cholesterol biosynthesis.

Nature Communications · Dec 15, 2025Peer-reviewedCancer Biology

A blueprint for mutation-defined hallmark vulnerabilities across human cancers

Ran Xu, Rebecca San Gil, Xin Tracy Liu, Yanfei Qi, Derek Tran, Chun Xu, Justin J. -L. Wong, Lenka Munoz, Graham J. Mann, Yuchen Feng

This paper maps mutation-defined cancer vulnerabilities across 22 cohorts, identifying OXPHOS addiction in CDKN2A-loss LUSC and highlighting drug repurposing opportunities using a machine learning framework.

bioRxiv · Oct 24, 2025 · PreprintCancer Biology

Enhanced Detection of Glioblastoma Vasculature with Superparamagnetic Iron Oxide Nanoparticles and MRI

Phillip W. Janowicz, Thomas Boele, Richard T. Maschmeyer, Yaser Hadi Gholami, Emma G. Kempe, Brett William Stringer, Shihani P. Stoner, Marie Zhang, Taymin du Toit‐Thompson, Fern Williams, Aude Touffu, Lenka Munoz, Zdenka Kuncic, Caterina Brighi, David E. J. Waddington

This study uses superparamagnetic iron oxide nanoparticles with MRI to improve detection of glioblastoma vasculature and angiogenesis beyond conventional MRI contrast.

Scientific Reports · Apr 24, 2025Peer-reviewedCancer Biology